IRVINE, Calif.--(BUSINESS WIRE)--April 25, 2006--Endologix, Inc. (Nasdaq:ELGX - News) today announced receipt of the U.S. Food and Drug Administration’s (FDA) approval to market new short body/short limb variants of the Powerlink® System endoluminal stent graft (ELG) for the minimally invasive treatment of abdominal aortic aneurysms (AAA). The company expects that the two Powerlink-120 models will address 5-10% of AAA patients currently excluded from treatment due to anatomical considerations. Endologix plans to begin marketing the new devices in May of this year.